Welcome to our dedicated page for Indivior Pharmaceuticals news (Ticker: INDV), a resource for investors and traders seeking the latest updates and insights on Indivior Pharmaceuticals stock.
Indivior PLC (NASDAQ: INDV) generates a steady flow of news centered on its role in treating opioid use disorder (OUD) and on the performance of its key product, SUBLOCADE. Company updates frequently combine clinical, operational, and financial information, reflecting both its pharmaceutical focus and its status as a Nasdaq-listed small-cap healthcare stock.
News coverage commonly includes earnings releases and financial guidance, where Indivior reports net revenue, SUBLOCADE net revenue, non-GAAP operating expenses, and adjusted EBITDA. These announcements often discuss progress under the Indivior Action Agenda, a multi-year operational roadmap that emphasizes U.S. SUBLOCADE growth, organizational simplification, and margin expansion.
Another major news theme is clinical and real-world evidence for SUBLOCADE and long-acting injectable buprenorphine. Indivior regularly reports results from randomized trials and open-label studies published in journals such as JAMA Network Open, as well as poster presentations at professional meetings. These items detail outcomes such as rapid reductions in opioid use, improved treatment retention, differences between maintenance doses, and associations between adherence and healthcare resource utilization.
Investors and healthcare professionals will also find corporate and strategic announcements, including index inclusions like the S&P SmallCap 600, participation in healthcare investor conferences, and steps in the company’s plan to redomicile from the U.K. to the U.S. Regulatory and legal developments, such as the conclusion of a legacy U.S. Department of Justice resolution agreement, are disclosed through press releases and Form 8-K filings.
This news page aggregates these various updates so readers can track Indivior’s financial performance, strategic initiatives, clinical research outputs, and regulatory milestones related to its OUD-focused pharmaceutical business.
Indivior PLC (Nasdaq/LSE: INDV) has appointed Patrick Barry as Chief Commercial Officer, effective June 2, 2025. Barry, a seasoned pharmaceutical executive with over 30 years of experience, will lead the company's commercial growth strategy and operations, focusing on advancing the treatment of opioid use disorder through SUBLOCADE®. Previously serving as executive vice president and chief commercial officer at Endo Pharmaceuticals, Barry managed commercial activities across three U.S. business segments with approximately $2 billion in revenue. His extensive career includes over two decades at Sanofi in various senior leadership positions. Barry holds an MBA from Cornell University and will join Indivior's executive committee.
Indivior PLC (NASDAQ/LSE: INDV) has announced its participation in three major investor events in June 2025. CEO Joe Ciaffoni and CFO Ryan Preblick will attend:
1. Jefferies Global Healthcare Conference in New York City on June 4th, featuring 1x1/group meetings and a fireside discussion at 9:55 a.m. ET (publicly available via webcast)
2. Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 11th, hosting 1x1/group meetings
3. Northland Growth Conference 2025, a virtual event on June 25th, conducting 1x1/group meetings
Interested investors need to contact their respective conference representatives to schedule meetings.
Indivior (Nasdaq/LSE: INDV) has announced the release of its Q1 2025 financial results for the period ending March 31, 2025. The company has made available its earnings release and investor presentation on their corporate website www.indivior.com.
A live webcast presentation is scheduled for 13:00 BST (8:00 am ET), to be hosted by CEO Mark Crossley. Participants can access the presentation through a webcast link or join telephonically by registering through the provided registration link.
Indivior PLC (NASDAQ/LSE: INDV) has announced significant changes to its Board of Directors, following previous appointments and discussions with Oaktree Capital Management. The key changes include:
- Reducing board size to seven directors for the 2025 AGM
- Peter Bains and Jo LeCouilliard will not seek re-election
- Robert Schriesheim stepped down effective March 2, 2025
- Search for one new Independent Non-Executive Director by July 1, 2025
- Daniel Ninivaggi appointed as Chair of Nomination Committee from March 10, 2025
- Barbara Ryan to become Chair of Compensation Committee after AGM
- Discontinuation of Operational Committee
These changes follow recent appointments including Dr. David Wheadon as Chair, Daniel Ninivaggi as Independent Non-Executive Director, and Joe Ciaffoni as CEO. The company has entered an amended Relationship Agreement with Oaktree Capital Management.
Indivior PLC (INDV) has appointed Joe Ciaffoni as its new Chief Executive Officer, effective upon shareholder approval at the May 2025 AGM. Ciaffoni, 53, who joined as an Independent Non-Executive Director in December 2024, brings over 30 years of pharmaceutical and biotech experience, having previously served as President and CEO of Collegium Pharmaceutical.
Current CEO Mark Crossley will step down following his tenure since June 2020, but will remain to support the transition until at least May 2025. Under Crossley's leadership, the company strengthened its commitment to patients and expanded treatment access for substance use disorders.
Ciaffoni's appointment aims to fuel Indivior's next growth phase in addiction treatment, where the company maintains a global portfolio of OUD treatments and employs over 1,000 individuals with products available in more than 30 countries.
Indivior (NASDAQ/LSE: INDV) announced FDA approval of significant label changes for SUBLOCADE®, their treatment for moderate to severe opioid use disorder (OUD). The key updates include a rapid initiation protocol that reduces treatment initiation time from one week to one hour, and new alternative injection sites including abdomen, thigh, buttock, and back of upper arm.
The rapid initiation protocol allows healthcare providers to start SUBLOCADE treatment after a single dose of transmucosal buprenorphine and a one-hour observation period. A non-inferiority study with 729 participants demonstrated the effectiveness of rapid initiation, with 66.4% of patients in the rapid induction arm receiving a second injection compared to 54.5% in the standard induction arm. Of the study participants, 77.5% were fentanyl-positive at induction.
These changes aim to reduce treatment obstacles and improve patient adherence while maintaining SUBLOCADE's established safety profile and efficacy.
Indivior PLC (Nasdaq/LSE: INDV) has announced its financial results for the fiscal year and fourth quarter of 2024, ending December 31, 2024. The company will host a live webcast presentation at 13:00 BST (8:00 am ET), led by CEO Mark Crossley.
The earnings release and investor presentation materials are available on the company's website at www.indivior.com. Participants can join the presentation through a webcast link or register for telephonic access.
Indivior PLC (Nasdaq/LSE: INDV) announced that the FDA has delayed the final review of proposed label changes for SUBLOCADE® (buprenorphine extended-release) Injection. The PDUFA action date was originally scheduled for February 7, 2025. On February 11, 2025, the FDA informed Indivior that while there were no outstanding items to address following acceptance of the proposed label, the final review has been delayed. The proposed changes include rapid initiation protocol and alternative injection sites. The company will provide updates on the approval status as appropriate.